Lawrence Otto Klein - 15 Jun 2026 Form 4 Insider Report for Oruka Therapeutics, Inc. (ORKA)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ORKA
Reported as of: 15 Jun 2026
Net transaction value: -$120,494
SEC form: 4
Accepted by SEC: 15 Jun 2026, 18:52:55 UTC
Prior SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Paul Quinlan, as attorney-in-fact for Lawrence Klein

Key filing fact

Lawrence Otto Klein filed Form 4 for Oruka Therapeutics, Inc. (ORKA) on 15 Jun 2026.

Key facts

This page summarizes Lawrence Otto Klein's Form 4 filing for Oruka Therapeutics, Inc. (ORKA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Jun 2026, 18:52.

Change

Previous filing in this sequence was filed on 11 Jun 2026.
Current net transaction value: -$120,494.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001762583 Primary reporting owner

Klein Lawrence Otto

Relationship: Chief Executive Officer, Director
Address: C/O ORUKA THERAPEUTICS, INC., 855 OAK GROVE AVE., SUITE 100, MENLO PARK
Signature: /s/ Paul Quinlan, as attorney-in-fact for Lawrence Klein
Signature date: 15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORKA transaction

Common Stock

Sale

Transaction value: $120,494
Shares: -1,729
Change %: -0.19%
Price: $69.69
Shares after: 925,580
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.